REGULATION OF DIGITAL HEALTH AND BIOTECHNOLOGY CONTENT MODERATION IN JAPAN

1. INTRODUCTION

Digital health biotechnology content moderation in Japan concerns the legal and ethical regulation of online information relating to biotechnology, medical technologies, genetic testing, genomic research, digital therapeutics, artificial intelligence (AI)-based diagnosis, and health-related applications. It includes controlling misleading medical advertisements, fraudulent biotechnology claims, unsafe treatment recommendations, unauthorized disclosure of genetic information, and deceptive digital health services.

Japan does not have a single statute specifically governing digital health biotechnology content moderation. Instead, regulation operates through several laws addressing medical advertising, pharmaceutical promotion, consumer protection, personal information, telecommunications, and medical-device safety. The objective is to protect public health, prevent misinformation, safeguard patient privacy, and maintain responsible digital communication without unnecessarily restricting legitimate scientific discussion.

2. PRINCIPAL LEGAL FRAMEWORK

A. Medical Care Act, 1948

The Medical Care Act regulates medical institutions and medical advertising. Article 6-5 restricts misleading, exaggerated, and otherwise prohibited medical advertising.

Digital advertisements promoting genetic testing, biotechnology treatments, regenerative medicine, or AI-based diagnostic services may fall within these restrictions when they constitute medical advertising. Medical institutions must ensure that online claims comply with applicable advertising standards.

B. Pharmaceuticals and Medical Devices Act (PMD Act), 2014

The PMD Act regulates pharmaceuticals, medical devices, and regenerative medicine products. Article 66 prohibits false or exaggerated advertising concerning medicines and medical devices, while Article 68 restricts advertising of unapproved medicines and medical devices for their intended use.

These provisions are relevant to online promotion of gene therapies, biotechnology-derived medicines, digital therapeutics, and AI-enabled medical devices.

C. Act on the Protection of Personal Information (APPI), 2003

The APPI governs the collection, use, storage, and disclosure of personal information. Medical histories, genetic information, and certain health-related information may qualify as special care-required personal information.

Digital health platforms must implement appropriate safeguards, obtain legally required consent where applicable, and prevent unauthorized disclosure of sensitive patient information.

D. Act on Specified Commercial Transactions, 1976

This legislation regulates specified commercial transactions, including certain online sales and marketing activities. It provides protections against misleading representations and improper commercial practices in relevant digital health transactions.

E. Telecommunications Business Act, 1984

The Act contains provisions concerning telecommunications services, including the handling of communications information and the responsibilities of relevant service providers. Its revised provisions concerning specified telecommunications services are relevant to privacy and transparency obligations for covered digital platforms.

3. CONTENT MODERATION REQUIREMENTS

Japanese digital health and biotechnology operators should adopt the following safeguards:

Medical misinformation control: Review claims concerning genetic treatments, disease prevention, diagnostic accuracy, and biotechnology products before publication or promotion.

Advertising compliance: Remove or correct prohibited misleading medical and pharmaceutical advertisements.

Privacy protection: Prevent unauthorized publication of patient records, genetic information, medical images, and identifiable clinical data.

Scientific transparency: Distinguish peer-reviewed research, experimental treatments, approved products, and unverified commercial claims.

AI-generated health content: Establish appropriate human oversight and procedures for correcting potentially harmful diagnostic or treatment information.

Consumer protection: Provide accurate pricing, product descriptions, limitations, and information about the regulatory status of biotechnology services.

4. LIABILITY AND ENFORCEMENT

Violations may result in administrative orders, corrective advertising requirements, business restrictions, civil liability, and criminal penalties where the relevant statutory provisions establish such consequences.

The PMD Act can impose liability for prohibited pharmaceutical advertising. The Medical Care Act can address unlawful medical advertising. The APPI provides regulatory mechanisms for personal-information violations.

Platforms, advertisers, healthcare institutions, biotechnology manufacturers, and medical professionals may have different responsibilities depending on their actual roles and applicable legislation. A platform is not automatically liable for every inaccurate statement uploaded by a third party.

5. RELEVANT CASE LAWS

Japan has limited reported judicial authority specifically addressing biotechnology content moderation. The following decisions provide relevant direct or analogous legal principles:

Supreme Court, 1981 – Pharmaceutical Side-Effects Case: The Supreme Court's pharmaceutical product-liability jurisprudence is relevant by analogy to public safety, pharmaceutical warnings, and misleading health-related claims.

Supreme Court, 2000 – Jehovah's Witness Blood Transfusion Case: The judgment emphasizes patient autonomy and informed medical decision-making. It provides analogous principles for digital health information and treatment-choice transparency.

Supreme Court, 2001 – Medical Negligence Jurisprudence: Medical professional responsibility provides analogous guidance for inaccurate digital medical recommendations that contribute to foreseeable patient harm.

Supreme Court, 2002 – Internet Publication and Defamation Jurisprudence: Japanese internet defamation decisions provide relevant principles concerning unlawful online publication, reputation, and the balance between expression and individual rights.

Supreme Court, 2017 – Google Search Results Case: The Court considered the removal of search-result information and the balancing of privacy interests against the public interest in information. Its reasoning is relevant to requests for removal of sensitive health-related information.

Supreme Court, 2022 – Internet Platform Information Disclosure Case: Japanese judicial developments concerning online information-disclosure procedures are relevant to identifying responsible parties in digital-content disputes.

These authorities should be distinguished from direct biotechnology-content moderation precedents. Their application is primarily analogous, particularly concerning privacy, medical responsibility, online expression, and unlawful publication.

6. INSTITUTIONAL COMPLIANCE RESPONSIBILITIES

Digital health companies and biotechnology platforms should establish content-review policies, maintain advertising substantiation records, protect sensitive health information, implement complaint-handling mechanisms, and establish procedures for correcting misleading medical claims.

Healthcare providers should ensure that digital communications are consistent with professional obligations. Biotechnology manufacturers should verify product claims against applicable regulatory approvals and scientific evidence.

7. CONCLUSION

Japan regulates digital health biotechnology content moderation through an interconnected legal framework involving the Medical Care Act, PMD Act, APPI, consumer protection legislation, and telecommunications regulation. These laws address misleading medical advertising, unsafe biotechnology promotion, unauthorized health-data disclosure, and digital consumer exploitation. Although Japan lacks a dedicated statute governing biotechnology content moderation, existing legal principles provide mechanisms for protecting patients, consumers, privacy, and scientific integrity while preserving legitimate online expression.